Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing cancer immunotherapies in the United States. The company develops various programs targeting immuno-oncology pathways, including AB928, a dual adenosine receptor antagonist, which is in a Phase I/Ib clinical trial; and AB122, an anti-PD-1 antibody that is in Phase I clinical trial.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone510-694-6200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$8.35 million
Profitability
Miscellaneous
Employees108
Next Earnings Date3/3/2020 (Estimated)
OptionableOptionable
Arcus Biosciences (NYSE:RCUS) Frequently Asked Questions
What is Arcus Biosciences' stock symbol?
Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS."
How were Arcus Biosciences' earnings last quarter?
Arcus Biosciences Inc (NYSE:RCUS) posted its quarterly earnings data on Tuesday, November, 5th. The company reported ($0.51) earnings per share for the quarter, missing the consensus estimate of ($0.49) by $0.02. The firm had revenue of $1.75 million for the quarter, compared to analyst estimates of $1.34 million. Arcus Biosciences had a negative return on equity of 38.73% and a negative net margin of 1,180.37%. View Arcus Biosciences' Earnings History.
When is Arcus Biosciences' next earnings date?
What price target have analysts set for RCUS?
5 brokerages have issued 12-month target prices for Arcus Biosciences' shares. Their forecasts range from $15.00 to $22.00. On average, they anticipate Arcus Biosciences' share price to reach $19.25 in the next year. This suggests a possible upside of 161.5% from the stock's current price. View Analyst Price Targets for Arcus Biosciences.
What is the consensus analysts' recommendation for Arcus Biosciences?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Arcus Biosciences.
Has Arcus Biosciences been receiving favorable news coverage?
News coverage about RCUS stock has been trending very negative recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies negative and positive press coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Arcus Biosciences earned a daily sentiment score of -3.0 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for Arcus Biosciences.
Are investors shorting Arcus Biosciences?
Arcus Biosciences saw a decrease in short interest in October. As of October 31st, there was short interest totalling 1,590,000 shares, a decrease of 20.9% from the September 30th total of 2,010,000 shares. Based on an average trading volume of 245,600 shares, the short-interest ratio is currently 6.5 days. Currently, 5.8% of the shares of the company are sold short. View Arcus Biosciences' Current Options Chain.
Who are some of Arcus Biosciences' key competitors?
Some companies that are related to Arcus Biosciences include Nabriva Therapeutics (NBRV), Gossamer Bio (GOSS), Epizyme (EPZM), Dicerna Pharmaceuticals (DRNA), Constellation Pharmaceuticals (CNST), Innoviva (INVA), Enanta Pharmaceuticals (ENTA), BELLUS Health (BLUSF), Supernus Pharmaceuticals (SUPN), Y-mAbs Therapeutics (YMAB), Radius Health (RDUS), Esperion Therapeutics (ESPR), ZEALAND PHARMA/S (ZEAL), Odonate Therapeutics (ODT) and Arvinas (ARVN).
What other stocks do shareholders of Arcus Biosciences own?
Who are Arcus Biosciences' key executives?
Arcus Biosciences' management team includes the folowing people:
- Dr. Terry Rosen Ph.D., Co-Founder, Chairman & CEO (Age 59)
- Dr. Juan Carlos Jaen, Co-Founder, Pres & Director (Age 61)
- Mr. Steven Chan, Consultant (Age 47)
- Ms. Rekha Hemrajani, Chief Operating & Financial Officer (Age 49)
- Dr. Stephen Young Ph.D., VP of Technology (Age 50)
When did Arcus Biosciences IPO?
(RCUS) raised $99 million in an IPO on Thursday, March 15th 2018. The company issued 7,100,000 shares at $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners acted as the underwriters for the IPO.
Who are Arcus Biosciences' major shareholders?
Arcus Biosciences' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Parallel Advisors LLC (0.19%), Rhumbline Advisers (0.11%), Russell Investments Group Ltd. (0.05%), California Public Employees Retirement System (0.04%), Bailard Inc. (0.03%) and Meeder Asset Management Inc. (0.01%). Company insiders that own Arcus Biosciences stock include Juan C Jaen, Kathryn E Falberg and Terry J Rosen. View Institutional Ownership Trends for Arcus Biosciences.
Which institutional investors are selling Arcus Biosciences stock?
Which institutional investors are buying Arcus Biosciences stock?
RCUS stock was bought by a variety of institutional investors in the last quarter, including Parallel Advisors LLC, California Public Employees Retirement System, Russell Investments Group Ltd., Rhumbline Advisers and Meeder Asset Management Inc.. Company insiders that have bought Arcus Biosciences stock in the last two years include Juan C Jaen, Kathryn E Falberg and Terry J Rosen. View Insider Buying and Selling for Arcus Biosciences.
How do I buy shares of Arcus Biosciences?
Shares of RCUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Arcus Biosciences' stock price today?
One share of RCUS stock can currently be purchased for approximately $7.36.
How big of a company is Arcus Biosciences?
Arcus Biosciences has a market capitalization of $337.53 million and generates $8.35 million in revenue each year. The company earns $-49,590,000.00 in net income (profit) each year or ($1.43) on an earnings per share basis. Arcus Biosciences employs 108 workers across the globe.View Additional Information About Arcus Biosciences.
What is Arcus Biosciences' official website?
How can I contact Arcus Biosciences?
Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The company can be reached via phone at 510-694-6200 or via email at [email protected]
MarketBeat Community Rating for Arcus Biosciences (NYSE RCUS)
MarketBeat's community ratings are surveys of what our community members think about Arcus Biosciences and other stocks. Vote "Outperform" if you believe RCUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RCUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
